PURPOSE: We sought to review outcomes in patients with stage IVB carcinoma of the cervix treated with irradiation in combination with chemotherapy. MATERIALS AND METHODS: We report outcomes of 24 consecutive patients with good performance status treated from 1998 to 2005. Most of these patients underwent concurrent irradiation with platinum-based chemotherapy. Some patients received subsequent systemic chemotherapy. RESULTS: All patients underwent external beam radiotherapy; 7 patients (29%) had additional high-dose-rate and 12 (50%) low-dose-rate brachytherapy. Two patients (8%) received an IMRT boost instead of brachytherapy. The mean dose to point A was variable (73.9 +/- 19.2 Gy). Twenty patients (83%) received radio-sensitizing platinum-based chemotherapy, and the remaining had radiotherapy alone. Seven patients (29%) had further combination chemotherapy. Therapy was well tolerated. The overall survival was 44% at 36 months and 22% at 5 years. CONCLUSION: Patients with stage IVB cervical cancer have mostly been treated with palliative intent. With the advent of concurrent chemoradiation, we have treated many of these cases with aggressive combination therapy. In this series, the use of radiotherapy and multiagent chemotherapy in patients with stage IVB cervical carcinoma and good performance status was well tolerated and resulted in higher survival rates than previously reported.
PURPOSE: We sought to review outcomes in patients with stage IVB carcinoma of the cervix treated with irradiation in combination with chemotherapy. MATERIALS AND METHODS: We report outcomes of 24 consecutive patients with good performance status treated from 1998 to 2005. Most of these patients underwent concurrent irradiation with platinum-based chemotherapy. Some patients received subsequent systemic chemotherapy. RESULTS: All patients underwent external beam radiotherapy; 7 patients (29%) had additional high-dose-rate and 12 (50%) low-dose-rate brachytherapy. Two patients (8%) received an IMRT boost instead of brachytherapy. The mean dose to point A was variable (73.9 +/- 19.2 Gy). Twenty patients (83%) received radio-sensitizing platinum-based chemotherapy, and the remaining had radiotherapy alone. Seven patients (29%) had further combination chemotherapy. Therapy was well tolerated. The overall survival was 44% at 36 months and 22% at 5 years. CONCLUSION:Patients with stage IVB cervical cancer have mostly been treated with palliative intent. With the advent of concurrent chemoradiation, we have treated many of these cases with aggressive combination therapy. In this series, the use of radiotherapy and multiagent chemotherapy in patients with stage IVB cervical carcinoma and good performance status was well tolerated and resulted in higher survival rates than previously reported.
Authors: J P Curtin; J A Blessing; K D Webster; P G Rose; A R Mayer; W C Fowler; J H Malfetano; R D Alvarez Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: A Cerrotta; G Gardan; R Cavina; F Raspagliesi; B Stefanon; I Garassino; R Musumeci; S Tana; G De Palo Journal: Eur J Gynaecol Oncol Date: 2002 Impact factor: 0.196
Authors: Harry J Long; Brian N Bundy; Edward C Grendys; Jo Ann Benda; D Scott McMeekin; Joel Sorosky; David S Miller; Lynne A Eaton; James V Fiorica Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: Amy D Tiersten; Meredith J Selleck; Dawn L Hershman; D Smith; Edward E Resnik; Andrea B Troxel; Lois B Brafman; Laureen Shriberg Journal: Gynecol Oncol Date: 2004-02 Impact factor: 5.482
Authors: Alexander Lin; Sirui Ma; Farrokh Dehdashti; Stephanie Markovina; Julie Schwarz; Barry Siegel; Matthew Powell; Perry Grigsby Journal: Int J Gynecol Cancer Date: 2019-02-09 Impact factor: 3.437
Authors: Jung Ho Im; Hong In Yoon; Sunghoon Kim; Eun Ji Nam; Sang Wun Kim; Ga Won Yim; Ki Chang Keum; Young Tae Kim; Gwi Eon Kim; Yong Bae Kim Journal: Radiat Oncol Date: 2015-04-04 Impact factor: 3.481
Authors: Jonathan S Berek; Koji Matsuo; Brendan H Grubbs; David K Gaffney; Susanna I Lee; Aoife Kilcoyne; Gi Jeong Cheon; Chong Woo Yoo; Lu Li; Yifeng Shao; Tianhui Chen; Miseon Kim; Mikio Mikami Journal: J Gynecol Oncol Date: 2018-12-28 Impact factor: 4.401